Repair Matrix – Advanced
The Repair Matrix – Advanced expands the Start protocol to six complementary compounds: BPC-157, TB-500, the copper peptide GHK-Cu, the anti-inflammatory tripeptide KPV, the tissue-protective ARA-290 and master-antioxidant Glutathione.
Built for deeper research into tissue repair, inflammation modulation and cellular resilience – a complete bundled set at a single discounted price.
Original price was: $414.99.$310.99Current price is: $310.99.
The expanded 6-part repair protocol: BPC-157, TB-500, GHK-Cu, KPV, ARA-290 and Glutathione.
What's included in this stack
Repair Matrix - Advanced - Expanded Six-Compound Repair Investigation
Description
Mechanism of Action
The Repair Matrix – Advanced bundle is designed for comprehensive investigation into tissue repair and inflammation modulation. BPC-157 and TB-500 are studied for angiogenesis, cell migration and systemic regeneration, while GHK-Cu is researched for collagen and extracellular-matrix remodeling. KPV is investigated for its anti-inflammatory action via melanocortin signaling, ARA-290 for innate-repair-receptor activation and tissue protection, and Glutathione for cellular redox balance, together offering a synergistic platform for advanced recovery research.
Benefits
- Enhanced Tissue Regeneration – The stack is researched for its ability to promote the regeneration and repair of diverse tissues, including connective tissues, muscles, and skin, with key contributions from BPC-157, TB-500, and GHK-Cu.
- Inflammation Modulation – The stack is studied for its capacity to reduce pro-inflammatory cytokines and oxidative stress, supporting a balanced immune response and cellular protection, as observed with BPC-157, GHK-Cu, KPV, ARA-290, and Glutathione.
- Enhanced Angiogenesis – The stack is investigated for its ability to promote new blood vessel formation and enhance microcirculation, improving nutrient and oxygen delivery to damaged tissues, a key effect of BPC-157, TB-500, and GHK-Cu.
- Gut Barrier Integrity – The stack is researched for its capacity to support the integrity and stability of the gastrointestinal tract lining, reducing inflammation and enhancing epithelial regeneration, notably through BPC-157 and KPV.
- Neuroprotection & Repair – The stack is studied for its neuroprotective properties and ability to enhance neuronal regeneration and functional recovery following nerve injury, with contributions from BPC-157, ARA-290, and Glutathione.
- Cellular Longevity Support – The stack is investigated for its role in protecting cells from oxidative damage, supporting mitochondrial health, and influencing gene expression related to longevity and repair, as seen with GHK-Cu, ARA-290, and Glutathione.
- Organ Detoxification – The stack is researched for its capacity to support liver detoxification pathways and protect various organs from induced damage, primarily through the actions of Glutathione and BPC-157.
- Anti-Fibrotic Remodeling – The stack is studied for its anti-fibrotic properties, helping to reduce excessive scar tissue formation and promote more balanced tissue remodeling during recovery, as observed with TB-500 and GHK-Cu.
Research Data
BPC-157
| Study / Model | Reported effect |
| Rat Achilles tendon transection | Accelerated tendon reattachment and increased collagen fiber density. |
| Gastrointestinal ulcer models (rats) | Rapid restoration of mucosal lining and epithelial integrity. |
| Muscle injury (crush and transection) | Enhanced angiogenesis and muscle fiber regeneration. |
| Peripheral nerve crush model | Improved axonal outgrowth and functional nerve recovery. |
| Liver toxicity (ethanol/NSAID models) | Reduced hepatocellular necrosis and oxidative stress. |
| Vascular injury models | Stimulated angiogenic repair and normalized blood vessel architecture. |
| Joint and ligament repair | Promoted fibroblast activity and accelerated tendon-to-bone healing. |
TB-500 (Thymosin beta 4)
| Study / Model | Reported effect |
|---|---|
| Rat full-thickness skin wound model | ↑ Wound closure rate, ↑ keratinocyte migration, accelerated re-epithelialization |
| Murine cardiac infarction model | ↓ Scar formation, ↑ cardiomyocyte survival and epicardial progenitor activation |
| Rat Achilles tendon injury | ↑ Collagen fiber organization and tensile strength during repair phase |
| Corneal injury models (rabbit) | Accelerated epithelial regeneration and reduced inflammatory infiltrate |
| In vitro endothelial cell culture | ↑ Angiogenic tube formation and VEGF-mediated vascular sprouting |
| Murine CNS injury model | ↑ Oligodendrocyte differentiation and neurological functional recovery |
| Skeletal muscle crush injury (rat) | ↑ Satellite cell activation, ↓ fibrotic tissue deposition |
GHK-Cu
| Study / Model | Reported effect |
| Human dermal fibroblast culture | ↑ Collagen and elastin synthesis; enhanced wound closure rate. |
| In vivo wound model (rats) | Accelerated epithelial repair and angiogenesis. |
| Gene expression profiling (human skin) | Activation of >400 regenerative genes, suppression of inflammatory markers. |
| Hair follicle cell culture | ↑ Anagen phase duration; increased dermal papilla cell proliferation. |
| UV-damaged skin model | ↓ oxidative stress and apoptosis; ↑ SOD and catalase activity. |
| Topical and subQ administration (clinical) | Improved elasticity, firmness, and wrinkle depth reduction. |
| In vitro antioxidant assays | Cu(II) chelation reduces reactive oxygen species (ROS). |
KPV
| Study / Model | Reported effect |
|---|---|
| DSS-induced colitis (mouse model) | ↓ colonic inflammation, ↓ TNF-α and IL-6 expression, improved mucosal recovery |
| Oral nanoparticle-delivered KPV (IBD models) | Reduced histological damage and restored epithelial barrier integrity |
| Atopic dermatitis (murine skin model) | ↓ skin lesion severity, ↓ mast cell infiltration, suppressed Th2 cytokines |
| In vitro macrophage culture (LPS-stimulated) | Inhibited NF-kB nuclear translocation, ↓ pro-inflammatory cytokine output |
| Keratinocyte and fibroblast assays | ↓ inflammatory signaling, supported wound closure dynamics |
| Allergic contact dermatitis model | Attenuated edema, reduced leukocyte infiltration at lesion sites |
| Intestinal epithelial cell lines | Decreased NF-kB activation and restored tight junction protein expression |
ARA-290 (Cibinetide)
| Study/model | Effect of ARA-290 |
| Diabetic neuropathy (human observational studies) | Improved sensory nerve function and reduced neuropathic pain markers |
| Peripheral nerve crush injury (animal model) | ↑ regenerating axonal fibers by ~60% |
| Spinal nerve ligation (animal model) | ↓ neuroinflammation and preserved myelin structure |
| Ischemic injury models | ↓ tissue necrosis and inflammatory cytokines (IL-6, TNF-α) |
| Erythropoietin knockout comparisons | Preserved cytoprotective effects without hematologic activation |
Glutathione
| Study/model | Reported effect |
| Human trials (oral and IV administration) | ↑ Plasma GSH levels, ↓ oxidative biomarkers (MDA, 8-OHdG) |
| Animal oxidative stress models | ↓ Lipid peroxidation and improved mitochondrial GSH:GSSG ratio |
| Hepatotoxicity models (CCl4, acetaminophen) | ↓ ALT/AST, ↓ hepatic necrosis, improved antioxidant enzyme activity |
| Neurodegenerative disease models | Protection of dopaminergic neurons and ↓ oxidative stress markers |
| In vitro melanocyte cultures | ↓ Tyrosinase activity and melanin synthesis via GSH-mediated inhibition |
| Inflammatory models | ↓ TNF-α, IL-6, and CRP, supporting immunomodulatory roles |
| Pharmacokinetic assessments | ↑ Cellular uptake with liposomal and SubQ formulations |
Stack Suggestions
This bundle is suited for researchers investigating complex tissue injury, chronic inflammation and cellular resilience in advanced research models, providing a robust framework across repair, anti-inflammatory and antioxidant pathways.
Pen Dosage Chart
BPC-157
| BPC-157 Pen 5 mg | |
| Volume | 2.0 mL |
| mg/mL | 2.5 mg/mL |
| Click-to-Dose | 1 click = 0.025 mg |
| Example(s) | 10 clicks = 0.25 mg |
| BPC-157 Pen 10 mg | |
| Volume | 2.0 mL |
| mg/mL | 5 mg/mL |
| Click-to-Dose | 1 click = 0.05 mg |
| Example(s) | 10 clicks = 0.50 mg |
TB-500 (Thymosin beta 4)
| TB-500 Pen 5 mg | |
|---|---|
| Volume | 2.0 mL (after reconstitution) |
| mg/mL | 2.5 mg/mL |
| Click-to-Dose | 1 click = 0.025 mg |
| Example(s) | 20 clicks = 0.5 mg; 40 clicks = 1 mg |
| TB-500 Pen 10 mg | |
|---|---|
| Volume | 2.0 mL (after reconstitution) |
| mg/mL | 5.0 mg/mL |
| Click-to-Dose | 1 click = 0.05 mg |
| Example(s) | 20 clicks = 1 mg; 40 clicks = 2 mg |
GHK-Cu
| GHK-Cu 100 mg | |
| Volume | 2.0 mL |
| mg/mL | 50 mg/mL |
| Click-to-Dose | 1 click = 0.50 mg |
| Example(s) | 10 clicks = 5 mg |
KPV
| KPV Pen 10 mg | |
|---|---|
| Volume | 2 mL |
| mg/mL | 5 mg/mL |
| Click-to-Dose | 1 click = 0.05 mg |
| Example(s) | 10 clicks = 0.5 mg |
ARA-290 (Cibinetide)
| ARA-290 (Cibinetide) Pen 10 mg | |
|---|---|
| Volume | 2 mL |
| mg/mL | 5 mg/mL |
| Click-to-Dose | 1 click = 0.05 mg |
| Example(s) | 10 clicks = 0.5 mg |
Glutathione
| Glutathione Pen 1500 mg | |
|---|---|
| Volume | 3 mL |
| mg/mL | 500 mg/mL |
| Click-to-Dose | 1 click = 5 mg |
| Example(s) | 10 clicks = 50 mg |
Dosage & Protocols Variations
BPC-157
Standard Research Protocol
- Dose: 0.2 – 0.4 mg (variant 5 mg pen = 8–16 clicks / variant 10 mg pen = 4–8 clicks)
- Duration: 2 – 4 weeks
- Frequency: Daily
- Cycle Interval: 2 – 4 weeks off before repeating
- Goal / Description: Common dose for general recovery models.
Therapeutic Research Protocol
- Dose: 0.5 – 0.75 mg (variant 5 mg pen = 20–30 clicks / variant 10 mg pen = 10–15 clicks)
- Duration: 4 – 6 weeks
- Frequency: Daily
- Cycle Interval: 4 weeks off before next cycle
- Goal / Description: Used in muscle or tendon repair studies.
Biohacker Protocol (experimental)
- Dose: 0.25 mg (variant 5 mg pen = 10 clicks / variant 10 mg pen = 5 clicks)
- Duration: Continuous
- Frequency: Daily
- Cycle Interval: Daily
- Goal / Description: Microdose for systemic recovery studies.
Stacked Protocol (BPC + TB-500)
- Dose: 0.25 mg + 0.25 mg (variant 5 mg pen = 10 clicks / variant 10 mg pen = 5 clicks)
- Duration: 4 weeks
- Frequency: 5× per week
- Cycle Interval: 2 – 3 weeks off between stacked cycles
- Goal / Description: Combined recovery and angiogenesis model.
TB-500 (Thymosin beta 4)
Standard Research Protocol
- Dose: 2 – 2.5 mg (variant 5 mg pen = 80–100 clicks / variant 10 mg pen = 40–50 clicks)
- Duration: 4 – 6 weeks
- Frequency: 2× per week
- Cycle Interval: 4 weeks off before repeating
- Goal / Description: Baseline protocol for systemic tissue repair and recovery research models.
Therapeutic Research Protocol
- Dose: 5 – 10 mg (variant 10 mg pen = 100–200 clicks)
- Duration: 4 – 6 weeks loading, then taper
- Frequency: Split into 2 – 3 weekly injections
- Cycle Interval: 4 – 6 weeks off before repeating
- Goal / Description: Higher-dose protocol used in connective tissue and musculoskeletal injury models.
Stacked Protocol (TB-500 + BPC-157)
- Dose: 2 mg TB-500 + 0.25 mg BPC-157 (variant 5 mg pen = 80 clicks / variant 10 mg pen = 40 clicks)
- Duration: 4 weeks
- Frequency: TB-500 2× weekly, BPC-157 daily
- Cycle Interval: 4 weeks off before repeating
- Goal / Description: Combined regenerative protocol investigated for synergistic tendon and ligament repair.
GHK-Cu
Standard Research Protocol
- Dose: 2 – 5 mg (= 4–10 clicks)
- Duration: 2 – 4 weeks
- Frequency: Daily
- Cycle Interval: 2-week pause
- Goal / Description: Used for baseline collagen and regeneration studies.
Therapeutic Research Protocol
- Dose: 5 – 10 mg (= 10–20 clicks)
- Duration: 4 – 8 weeks
- Frequency: 3 – 5× per week
- Cycle Interval: 4 weeks off
- Goal / Description: For advanced skin, wound, or hair research.
Biohacker Protocol
- Dose: 1 – 2 mg (= 2–4 clicks)
- Duration: 30 days
- Frequency: Daily
- Cycle Interval: Repeat monthly
- Goal / Description: Used for anti-aging and repair model observation.
KPV
Standard Research Protocol
- Dose: 0.2 – 0.5 mg (= 4–10 clicks)
- Duration: 4 – 6 weeks
- Frequency: Daily
- Cycle Interval: 2 – 4 weeks off before repeating
- Goal / Description: Baseline anti-inflammatory and cytokine modulation models.
Therapeutic Research Protocol
- Dose: 0.5 – 1 mg (= 10–20 clicks)
- Duration: 6 – 8 weeks
- Frequency: Daily
- Cycle Interval: 3 – 4 weeks off before repeating
- Goal / Description: Targeted gastrointestinal and mucosal inflammation research.
Biohacker Protocol (experimental)
- Dose: 0.1 – 0.25 mg (= 2–5 clicks)
- Duration: 8 – 12 weeks
- Frequency: Daily, continuous
- Cycle Interval: 1 – 2 weeks off every 8 weeks
- Goal / Description: Low-dose continuous NF-kB modulation studies.
Stacked Protocol (KPV + BPC-157)
- Dose: 0.25 – 0.5 mg KPV + 0.25 mg BPC-157 (= 5–10 clicks)
- Duration: 4 – 6 weeks
- Frequency: Daily
- Cycle Interval: 2 – 4 weeks off before repeating
- Goal / Description: Combined mucosal repair and inflammatory pathway research.
ARA-290 (Cibinetide)
Standard Research Protocol
- Dose: 2 – 4 mg (= 40–80 clicks)
- Duration: 4 – 12 weeks
- Frequency: Daily subcutaneous injection
- Cycle Interval: 2 – 4 weeks off before repeating
- Goal / Description: Baseline protocol for neuropathic and inflammatory research models.
Therapeutic Research Protocol
- Dose: 4 – 8 mg (= 80–160 clicks)
- Duration: 8 – 12 weeks
- Frequency: Daily
- Cycle Interval: 4 weeks off before repeating
- Goal / Description: Higher-dose investigation of small fiber neuropathy and sarcoidosis-related neuropathic models.
Biohacker Protocol (experimental)
- Dose: 1 – 2 mg (= 20–40 clicks)
- Duration: 6 – 8 weeks
- Frequency: 3 – 5× per week
- Cycle Interval: 2 weeks off before repeating
- Goal / Description: Low-dose continuous exposure for cytoprotective and anti-inflammatory pathway research.
Glutathione
Standard Antioxidant Protocol
- Dose: 200 – 400 mg (= 40–80 clicks)
- Duration: 4 – 8 weeks
- Frequency: 3× weekly
- Cycle Interval: 4-week rest
- Goal / Description: ↑ Systemic antioxidant capacity, baseline redox support
Intensive Detoxification Protocol
- Dose: 500 – 600 mg (= 100–120 clicks)
- Duration: 4 weeks
- Frequency: 5× weekly
- Cycle Interval: 8-week rest
- Goal / Description: Rapid ↑ GSH levels for detoxification models, tissue saturation
Maintenance Protocol
- Dose: 150 mg (= 30 clicks)
- Duration: 8 – 12 weeks
- Frequency: 3× weekly
- Cycle Interval: 8-week rest
- Goal / Description: Long-term maintenance of improved GSH status
Possible Side Effects
This bundle combines multiple research compounds; the per-compound safety notes below apply. For laboratory research use only – not for human consumption.
BPC-157
BPC-157 is generally well-tolerated in animal and limited human studies.
Reported side effects are rare and mild:
- Localized irritation or redness at injection site.
- Mild fatigue during initial dosing period.
- Transient headache or digestive sensitivity in sensitive subjects.
No evidence of hormonal, hepatic, or systemic adverse effects has been observed in available data.
TB-500 (Thymosin beta 4)
TB-500 is generally well-tolerated in animal studies and limited human observational reports.
Reported side effects in research contexts are uncommon and typically mild:
- Localized redness, tenderness, or irritation at the injection site.
- Transient fatigue or lethargy during the initial dosing period.
- Mild headache or lightheadedness reported in some subjects.
- Temporary flu-like sensations shortly after administration.
- Occasional digestive sensitivity or mild nausea.
No evidence of hormonal, hepatic, or systemic adverse effects has been observed in available preclinical data. As TB-500 is studied for its angiogenic and cell-migration properties, ongoing research continues to evaluate its long-term safety profile in experimental models.
GHK-Cu
GHK-Cu has been generally well-tolerated in research and cosmetic studies.
Mild redness, itching, or warmth may occur at the injection site due to copper’s vascular effects.
High concentrations in topical form may cause temporary skin irritation or dryness.
No systemic toxicity has been reported in human or animal studies.
Side effects are dose-dependent and typically resolve quickly after application adjustment.
KPV
KPV is generally well-tolerated in animal studies and limited human research models.
Reported side effects are rare and mild:
- Mild irritation or redness at the injection site.
- Transient flushing or warmth following administration.
- Occasional mild headache reported in early dosing.
- Slight gastrointestinal sensitivity in oral research formulations.
No evidence of hormonal, hepatic, or systemic adverse effects has been observed in available data.
ARA-290 (Cibinetide)
ARA-290 is generally well-tolerated in clinical and preclinical research, with no evidence of erythropoietic activity or thrombotic risk associated with full-length EPO.
Reported side effects in research settings are infrequent and mild:
- Transient injection-site reactions, including mild redness or irritation.
- Occasional headache or lightheadedness during initial dosing.
- Mild fatigue or drowsiness reported in some subjects.
- Rare gastrointestinal sensitivity, including nausea.
No significant changes in hematocrit, hemoglobin, or blood pressure have been observed, distinguishing ARA-290 from erythropoietin. No evidence of hepatic, renal, or cardiovascular adverse effects has been reported in available research data.
Glutathione
Glutathione supplementation is generally well-tolerated due to its endogenous nature, but some individuals may experience side effects, particularly with higher doses or sensitive constitutions. The most common adverse reactions are related to gastrointestinal adjustments and administration site responses with subcutaneous injection protocols.
Gastrointestinal Effects: Mild nausea, abdominal cramping, bloating, and flatulence may occur, especially during the initial supplementation period. These symptoms typically resolve as the body adapts to increased glutathione levels. Some users report a metallic or sulfur-like taste, which is attributed to the cysteine component of the molecule.
Injection Site Reactions: With subcutaneous administration, mild redness, swelling, or irritation at the injection site may occur. These reactions are typically transient and resolve within 24-48 hours. Proper injection technique and site rotation can minimize these effects.
Allergic Reactions: Although rare, some individuals may experience allergic responses including skin rashes, hives, or in severe cases, difficulty breathing. Those with known sensitivities to sulfur-containing compounds should exercise particular caution.
Respiratory Considerations: Individuals with asthma or respiratory sensitivities should avoid inhaled forms, as glutathione may trigger bronchospasms or respiratory distress in predisposed individuals.
Headaches and Fatigue: Some users report mild headaches or temporary fatigue during initial supplementation, likely related to detoxification processes and cellular adjustments to enhanced antioxidant capacity.
It is important to note that most side effects are mild, transient, and resolve with continued use or dosage adjustment. However, individuals should discontinue use and consult healthcare providers if adverse reactions persist or worsen.
Product Attributes
Scientific References
BPC-157
- Emerging use of BPC-157 in orthopaedic sports medicine Animal | In vitro
- BPC-157 benefits, dosage, and side effects Observational | Animal | In vitro
- BPC 157: science-backed uses, benefits, dosage, and safety Observational | Animal | In vitro
- Pentadecapeptide BPC 157 enhances the growth hormone receptor expression Animal | In vitro
- Multifunctionality and possible medical application of the BPC 157 peptide Observational | Animal | In vitro
- BPC-157: miracle healing peptide or hidden danger? Observational | Animal | In vitro
- Stable gastric pentadecapeptide BPC 157: protective effects and healing mechanisms Animal | In vitro
- What is BPC-157? everything to know about this peptide Observational | Animal | In vitro
- The science of BPC-157 supplements Observational | Animal | In vitro
- What science actually says about BPC 157 benefits Observational | Animal | In vitro
TB-500 (Thymosin beta 4)
- Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications Observational | Animal | In vitro
- Thymosin beta4 and cardiac regeneration: are we missing a beat? Animal | In vitro
- Thymosin beta4 induces angiogenesis through Notch signaling in endothelial cells Animal | In vitro
- Thymosin beta4 promotes cardiac cell survival and tissue repair Animal | In vitro
- Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair Animal | In vitro
- Thymosin beta4 and tissue regeneration: a review of its therapeutic potential in wound healing Observational | Animal
- Thymosin beta-4: a multi-faceted tissue repair stimulating protein in heart injury Animal | In vitro
- Thymosin beta4 in the eye: from bench to bedside Observational | Animal | In vitro
GHK-Cu
- Expression of glycosaminoglycans and small proteoglycans in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ Animal
- The human tripeptide GHK-Cu in prevention of oxidative stress and inflammatory conditions Review
- Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data Review
- The potential of GHK as an anti-aging peptide Review
- GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration Review
- Thermodynamically stable ionic liquid microemulsions pioneer pathways for topical delivery and peptide retention In vitro
- Exploring the beneficial effects of GHK-Cu on an experimental model of DSS-induced ulcerative colitis in mice Animal
- The human tri-peptide GHK and tissue remodeling Review
- The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures In vitro
- In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds Animal
KPV
- Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases Observational | Animal | In vitro
- The tripeptide KdPT is hydrolytically stable and reduces TNF-α-induced pro-inflammatory mediators in human keratinocytes In vitro
- Targeted delivery of the tripeptide KPV via a nanoparticle drug delivery system attenuates colitis in mice Animal | In vitro
- Anti-inflammatory effect of the tripeptide KPV in cells and animal models of inflammatory bowel disease Animal | In vitro
- The anti-inflammatory tripeptide KPV inhibits NF-kB nuclear translocation, ICAM-1 expression and neutrophil recruitment In vitro
- KPV reduces inflammation in models of colitis and oxidative stress Animal | In vitro
- Alpha-MSH and its tripeptide KPV downregulate pro-inflammatory cytokine production in keratinocytes In vitro
- Lysine-proline-valine: a melanocortin-derived peptide with potent anti-inflammatory activity Animal | In vitro
ARA-290 (Cibinetide)
- ARA 290, a specific agonist of erythropoietin/CD131 heteroreceptor, improves circulating endothelial progenitors’ angiogenic potential and homing ability Human RCT | In vitro
- ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density Human RCT
- Effect of the innate immune modulator ARA 290 on inflammation-related biomarkers in patients with sarcoidosis: A phase 2a study Human RCT
- A nonhematopoietic erythropoietin analogue, ARA 290, inhibits macrophage activation and prevents damage to transplanted islets Animal | In vitro
- ARA290, a non-erythropoietic EPO derivative, attenuates renal ischemia/reperfusion injury Animal
- Cibinetide improves quality of life in patients with sarcoidosis-associated small fiber neuropathy Observational | Human RCT
- The non-hematopoietic erythropoietin analog ARA 290 attenuates neuropathic pain and acute inflammation Animal | In vitro
- Cibinetide reduces hyperalgesia and improves metabolic control in type 2 diabetes patients with neuropathy Human RCT
Glutathione
- Randomized controlled trial of oral glutathione supplementation on body stores of glutathione Human RCT
- Oral supplementation with liposomal glutathione elevates body stores of glutathione and markers of immune function Human RCT
- Glutathione synthesis in the mouse liver supports lipid abundance through NRF2 repression Animal
- Glutathione system enhancement for cardiac protection: pharmacological and clinical data from bench-to-bedside Observational
- Randomized clinical trial of how long-term glutathione supplementation improves lipid metabolism in obese patients with nonalcoholic fatty liver disease Human RCT
- ALSUntangled no. 52: glutathione Human RCT
- Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, clinical trial Human observational
- Systemic glutathione as a skin-whitening agent in adults Human RCT
- Clinical evaluation of glutathione concentrations after consumption of S-acetylglutathione: a pilot study Human observational
- Development of a mouse model expressing a bifunctional glutathione-synthesizing enzyme to study glutathione limitation in vivo Animal
Included In The Box
Every product arrives in a premium, custom-designed PEPTIDE.Power box, engineered for convenience, hygiene, and safe storage in your refrigerator. Inside, you will find everything needed for your full research protocol:
- 1× Disposable Pre-Mixed Injection Pen
- Powered by our proprietary PSM Technology™ – precision stabilization & mixing system for consistent potency
- 10× Ultra-thin Needles (33G, 4 mm)
- 10× Alcohol Pads for sterile preparation
- Internal Stabilizing Foam Insert to prevent shaking during transport
- Instruction Panel printed on the inside of the box for quick reference
- Security Seal Sticker ensuring the package has not been opened or tampered with
Storage
Store the product in a refrigerator at 1 – 8°C immediately upon delivery. To maintain optimal stability, keep the pen away from light, and do not expose it to repeated temperature changes.
Once reconstituted (all our pens come pre-mixed), research compounds remain stable for 6 – 8 weeks under proper refrigeration.
Do not freeze after reconstitution. Always keep the box closed so the pen, needles, and alcohol pads stay clean and protected.
For best results, use the product consistently within the recommended time window and always follow your research protocol.
Delivery
We ship with Next-Day EU Delivery via DHL Express or UPS Express.
All orders are prepared fresh on the day of dispatch, placed in EPS Cold-Chain Transport Boxes, and shipped with cooling elements to maintain a stable temperature throughout the journey.
Our logistics process is designed so the package arrives overnight, avoiding customs delays inside the European Union.
Products are shipped from our EU facility, ensuring no import duties, no customs clearance, and always fast and secure delivery.
Payment
Due to the nature of research peptides and the high-risk category assigned by payment processors, credit card companies do not generally support merchants in this field.
For this reason, we accept mainly Bank Transfers.
We also work with a crypto payment provider, and from time to time, card payments may be available depending on processor availability.
Within the European Union, SEPA transfers are fast, low-cost, and usually arrive within minutes to a few hours, making the payment process smooth and simple.
Once the transfer is received, your order is prepared immediately and dispatched the same day, depending on the daily cut-off time.
Please note that we do not dispatch shipments on Fridays or on days before official public holidays. This is done to ensure that parcels can be delivered on the next working day and are not held in transit over weekends or holidays.
This method ensures compliance, security, and continuity of service for all customers across the EU.
Didn't find the answer to your question?
View all frequently asked questions
